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Abstract
We report herein a method to track the migration of
dendritic cells (DCs) using optical imaging. With the
assistance of the delivery module, fluorescein iso-
thiocyanate (FITC) could internalize inside DCs within
15 minutes of incubation. The fluorescent signal was
mostly cytoplasmic and could be detected using
in vivo imaging. Furthermore, we observed that the
probe did not interfere with the DCs maturation as we
assessed the expression of several surface markers.
The labeled DCs secreted interleukin-12 (IL-12) and
tumor necrosis factor–alpha (TNF-A) and stimulated
the proliferation of CD4+ T lymphocytes responding to
lipopolysaccharide (LPS) stimulation. We have sys-
tematically compared the probe uptake between
mature and immature DCs. The study showed that the
latter phagocytosed the probe slightly better than the
former. Intravital imaging of treated mice showed
the migration of DCs to lymph nodes (LNs), which is
confirmed by immunohistochemistry. Taken together,
we demonstrated the potential use of optical imaging
for tracking the migration of DCs and homing in vivo.
The delivery molecules could also be used on other
imaging modalities or for delivery of antigens.
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Introduction
Dendritic cells (DCs) play an important role in the initiation
and development of adaptive immune responses against
bacteria, viruses, allergens, and tumor antigens [1]. They
are the most effective antigen-presenting cells because
they can capture and take up antigens in the peripheral
tissues and transport these antigens from the peripheral
sites to the primary and secondary lymphoid tissues for T-
cell presentation [2]. The functional characteristics of DCs
evolve with their stage of maturation [3]. Immature DCs
have no ability to activate T lymphocytes, but they are
strategically located at body surfaces and in interstitial
spaces of most tissues [4]. The primary function of this
stage of cellular development is to capture microbial protein
antigens through their active phagocytosis mechanisms.
During the migration to lymphoid tissues, DCs undergo
further differentiation that can be characterized by the loss
of phagocytotic capacity and increased expression of costimu-
latory surface molecules necessary for T-cell activation
through the major histocompatibility–peptide complexes. Re-
cently, several lines of research have demonstrated the suc-
cessful use of DCs for generating antitumor immune responses
in animals. In these studies, DCs were pulsed with tumor-
associated antigen peptide or protein to elicit antigen-specific
protective antitumor immunity in a number of murine models
[5,6]. This observation laid the foundation for several clinical
studies using the same approach [7–12]. The clinical works
showed promise, but the results have been mixed, mainly
because the progress in this area has been severely limited
by the lack of effective methods for monitoring the behavior
of DCs in vivo, both in animals, and more crucially, in human
following reinjection of activated DCs into the host system
[13,14]. Another hurdle in this field is that the majority of
the work depends on histological staining that requires the
sacrifice of the animals to determine the mobility and interac-
tion of DCs with other cells at the target sites [15], thus limiting
the ability to obtain information regarding the dynamic cell
migration, homing, and, importantly, cellular fate in a living
system. To achieve optimal and translational research parallel
to and eventually valuable to clinical applications, we decided
to use optical imaging as a means to track the migration of
DCs in vivo.
In this work, we describe a method to deliver a fluorescent
dye using amyristoylated polyarginine (11-mer) peptide (MPA11P)
module. The presence of a fluorescent dye enables us to quan-
tify the uptake at different stages of the development of DCs.
Most importantly, we can track cell migration to the peripheral
lymphatic tissue using the whole mouse optical imaging system
and the data are corroborated with immunohistochemistry.
Abbreviations: BrdU, bromodeoxyuridine; DC, dendritic cell; DIC, differential interference
contrast; FCS, fetal calf serum; FITC, fluorescein isothiocyanate; LN, lymph node; MPA11P,
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Adult C57BL/6 (H-2b) mice were obtained from The Jackson
Laboratory (Bar Harbor, ME). Animal experiments were
carried out in accordance with the guidelines provided by
Vanderbilt University Institutional Animal Care and Use
Committee (IACUC) and the National Institute of Health
Guide for the Care and Use of Laboratory Animals. Granu-
locyte/macrophage colony–stimulating factor (GM-CSF)
and interleukin-4 (IL-4) came from PeproTech (Rocky Hill,
NJ). Lipopolysaccharide (LPS) derived from Escherichia coli
and fluorescein isothiocyanate (FITC) were purchased
from Sigma-Aldrich (St. Louis, MO). Monoclonal antibodies
against CD16/CD32, CD11c, CD80, CD86, andCCR7 aswell
as their biotin-labeled isotypic antibodies were purchased
from eBioscience (San Diego, CA). Paired antibodies for
enzyme-linked immunosorbent assay (ELISA) detection of
tumor necrosis factor–alpha (TNF-a) and IL-12 and other
reagents for ELISA were also purchased from eBioscience.
T4 cell isolation and bromodeoxyuridine (BrdU)-based pro-
liferation kits were purchased from BD PharMingen (San
Diego, CA). RPMI 1640, fetal calf serum (FCS), and other
cell culture additives came from Invitrogen (Carlsbad, CA).
Dendritic Cells Preparation
Dendritic cells were isolated from mouse bone marrow as
described with slight modifications [16]. Briefly, marrow cells
were flushed out from femurs and tibias of C57BL/6 mice and
subsequently passed through wire mesh screens to obtain a
single cell suspension. Red cells were lysed with 0.83%
ammonium chloride twice with 2 minutes of incubation at
room temperature each time. The remaining cells were
cultured with RPMI 1640 supplemented with 10% FCS,
50 mM 2-mercaptoethanol, 100 mM sodium pyruvate, 100
U/ml penicillin, 100 mg/ml streptomycin, and 1000 U/ml
recombinant GM-CSF (rGM-CSF) and IL-4. On day 3 of
the culture, nonadherent granulocytes and the B and T
lymphocytes were gently removed by suction of 75% of the
medium and fresh media were added. The released imma-
ture, nonadherent cells were collected on day 5 with typical
morphologic features of DCs. Immature DCs were used on
day 6. Maturation of the DCs was achieved by culturing the
cells in a similar manner. On day 7, the DCs were stimulated
with 10 ng/ml TNF-a or 10 mg/ml LPS for 48 hours.
CD4+ T-Cells Preparation
A purified population of CD4+ T lymphocytes was
obtained from freshly harvested splenocytes by negative
selection columns with a CD4 magnet-bead, according to
the manufacturer’s specifications (BD PharMingen). Cells
purified using this method were 90% positive for selected
T-cell phenotype.
MPA11P-FITC Probe
The development of the MPA11P-FITC probe in this study
was described previously [17,18]. Briefly, a myristic acid
moiety was incorporated into the 11-mer polyarginine peptide
through a b-alanine spacer. The peptide also contains a
lysine analog at the C-terminal for dye labeling. FITC was
attached into the lysine side chain in the presence of diiso-
propylethylamine. The synthesized compound was purified
by high-performance liquid chromatography and character-
ized by matrix-assisted laser desorption and ionization time-
of-flight mass spectrometry; calculated: 2535.45, found:
2535.73 (M + H)+.
Labeling Dendritic Cells
The MPA11P-FITC probe was diluted at the indicated
concentrations with Hank’s balanced salt solution. Two milli-
liters of the probe was used in each 60-mm dish seeded with
0.5  106 cells. After incubating at 37jC in a humidified
atmosphere with 5% CO2 for either 15 or 60 minutes, the
excess probe was washed three times with phenol red–free
Hank’s balanced salt solution. The labeled cells were either
maintained in full-growth media for future experiments or
directly collected for fluorescence-activated cell sorting
(FACS) analysis to assess the labeling efficiency. FITC alone
was used as a reference control while quantifying the probe
uptake in both immature and mature DCs. When assessing
the effect of probe labeling on the function of DCs, such as
surface marker expression and cytokine secretions, the
controls were the untreated immature DCs.
Fluorescence Microscopy on Live Cells
Mature or immature DCs (2.0  104) were plated in
separate wells of an eight-well chamber (Nalge Nunc Inter-
national, Rochester, NY) in full-growth medium overnight.
The cells were then labeled with either 0.2 mM of FITC
(control) or MPA11P-FITC for 15 minutes at 37jC in a 5%
CO2–equipped incubator. Cells were washed three times with
PBS and directly examined under a fluorescence microscope
with the cells covered by a thin layer of PBS. Confocal micros-
copy of the unfixed cells was performed using an inverted
microscope (LSM510; Zeiss, Thornwood, NY). Images were
acquired with 488-nm excitation and 515-nm emission for both
control FITC and MPA11P-FITC. Transmitted light differential
interference contrast (DIC) images were also acquired.
Enzyme-Linked Immunosorbent Assay
Enzyme-linked immunosorbent assay was used to quan-
tify the secreted IL-12 and TNF-a during the DCs’ matura-
tion. Briefly, a 96-well plate (Corning, Lowell, MA) was coated
with 0.2 mg of purified anti–IL-12 or anti–TNF-a antibody
(eBiosciences) in 100 ml of PBS overnight at 4jC, washed
twice with PBS–T (0.05% Tween-20 in PBS), and nonspecific
binding blocked for 3 hours at room temperature with 5% BSA
in PBS. The plates were washed and aliquots (10, 50, and
100 ml) of centrifuged culture medium were added into the
plate (the volume wasmade up to 100 ml with fresh culture me-
dium). The plates were then incubated for 2 hours at room
temperature, followed by six washes with PBS–T. Purified and
biotinated conjugated monoclonal antibodies (100 ml of 1 mg)
against IL-1 and TNF-a in PBS–T and 1% BSA were added
to corresponding wells in the plates for 2 hours of incubation
at room temperature. The plate was washed and incubated
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with 100 ml of 1:500 (with PBS–T/1% BSA) diluted HRP–
avidin (eBiosicence) for 30 minutes at room temperature.
After washing (four times) with PBS–T and with PBS (twice),
colorimetric detection at 492 nm on the plate reader was
performed using O-phenylenediamine dihydrochloride as
substrate (Sigma FAST OPD tablet). Each sample was
measured in three different dilutions. Data were presented
as the average of a triplicate with standard deviation.
Phantom and In Vivo Optical Imaging
Optical imaging experiments were carried out on female
mice, 7 to 8 weeks of age. To enhance the detection in an in
vivo study, we briefly incubated mature DCs with freshly
developed probe (6 mM). Twomillion labeled DCs were adap-
tively transferred to C57BL/6 mice through subcutaneous
(s.c.) injection. Right after injection, animals were anesthe-
tized with isoflurane and imaged as an initial point. Twenty-
four–hour postinjection, the same process was repeated. Then
the lymph nodes (LNs) were exposed and imaged. Phantom
and in vivo imaging were performed using a fluorescence re-
flectance whole-mouse system (IVIS 200; Xenogen, Cranbury,
NJ). Images were acquired using the IVIS imaging system
with the excitation at 490 nm and the fluorescence was col-
lected through a long-pass filter. Data were analyzed by Living
Image software version 2.5 (Cranbury, NJ).
Cell Surface Phenotyping
Surface antigens were analyzed on day 7 or 9 of the
culture following maturation by flow cytometry. Dendritic cells
were preincubated with anti–CD16/32 to block nonspecific
Fc interaction for 10 minutes. Aliquoted cells were then in-
cubated with biotinylated monoclonal antibodies specific for
selective surface markers of DC maturation (CD11c, CD80,
CD86, and CCR7) for 20 minutes at 4jC, washed twice with
PBS, and developed with streptavidin–phycoerythrin. The
control group was incubated with biotinylated isotypic im-
munoglobins and was also developed with streptavidin–
phycoerythrin. Flow cytometric analysis was performed
using a FACSCalibur (BD Biosciences, Mountain View, CA)
with CellQuest software (BD Biosciences). Gating was
performed according to light scattering properties, and
dead cells were excluded based on their forward/side scat-
ter pathway.
Mixed Leukocyte Reactivity Assay
The ability of DCs to stimulate quiescent T-cells was
assessed by the mixed leukocyte reactivity assay. Unstimu-
lated or LPS-stimulated DCs with or without labeling with
MPA11P-FITC were harvested, washed, and irradiated at a
dose of 30 Gy and plated at serial dilutions in 24-well plates.
These stimulator DCs were incubated for 3 days with 100,
20, and 5 (T-cell/DC ratio) splenic CD4+ T-cells in
RPMI 1640 media supplemented with 10% heat-inactivated
FCS, 2 mM glutamine, 100 U/ml penicillin, streptomycin, and
nonessential amino acids, and 1 mM sodium pyruvate, and
were then incubated at 37jC under 5% CO2 atmosphere
for 3 days. BrdU was added for the last 24 hours. BrdU
integration–based proliferation assay was performed with a
kit, using the procedure recommended by BD Bioscience.
Immunohistological Procedures
After completion of the in vivo imaging experiment, ani-
mals were sacrificed and the inguinal LNs were excised and
snap frozen in liquid nitrogen. Five-micrometer sections of
frozen LN tissues were placed on charged slides. The sam-
ples were treated with Ultra V block for 5 minutes (Labvision,
Fremont, CA) for nonspecific staining before primary anti-
body addition. Tissues were incubated with goat anti-CD3
(cat. # SC-1127; Santa Cruz Biotechnology, Inc., Santa Cruz,
CA) diluted 1:200 for 60 minutes followed by donkey anti–
goat Rhodamine (Invitrogen) at 1:500 for 30 minutes. Micros-
copy was performed using a confocal microscope (LSM
510Meta; Zeiss) equipped with an LSM Pascal Vario RGB
Laser Module (argon/2 458, 477, 488, and 514 nm; HeNe1
543 nm; and HeNe2 633 nm; Thornwood, NY). Images
with slice thickness of < 0.9 mm were acquired to produce
FITC and Rhodamine staining. Summation projection of all
background-corrected confocal slices was produced using
the LSM Pascal Software (v. 3.2 WS). Final confocal images
were color-coded green for FITC and red for Rhodamine.
Statistical Analysis
Data were expressed as means ± SD. Statistical differences
were performed using Student’s t test (GraphPad software,
San Diego, CA). Significance was considered for P < .05.
Results
The current challenge we face in tracking DCs in vivo is that
most imaging probes have low permeability for DCs. Al-
though described as antigen-presenting cells, DCs display
poor endocytic and phagocytic capacities [19,20]. Therefore,
we theorized that successful tracking of labeled DCs by
imaging would need a robust and expeditious delivery of
the probe inside the cells. In the present study, we test our
theory by using the previously described and reported novel
class of membrane translocation peptides to shuttle the
fluorescent dye inside the DCs, followed by an injection of
the labeled DCs into syngeneic mice for tracking the migra-
tion of the labeled cells using optical imaging. The amphi-
philic delivery module was composed of a myristic acid linked
to 11-mer polyarginine peptide (MPA11P) through a b-alanine
linker, whereas the fluorescent dye, FITC, was attached to
the delivery module through a lysine side chain [17].
We tested cell uptake by FACS analysis using two differ-
ent concentrations. There was minimal internalization of
FITC at a concentration of 0.2 mM in both mature and
immature DCs, even after 1 hour of incubation (Figure 1).
There was an insignificant fluorescent signal enhance-
ment when the FITC concentration increased to 1.0 mM.
However, we did not anticipate that the optical imaging
device could detect this diminutive internalized signal. This
is a fundamental difference between in vivo optical imaging
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and in vitro fluorescence microscopy. The latter has been
used mostly for imaging frozen sections for carboxylfluo-
rescein succinimidyl ester– labeled DCs [21]. By contrast,
when FITC was attached to MPA11P to form an MPA11P-
FITC probe with a final concentration of 0.2 mM, both mature
and immature DCs showed remarkable uptakes. When the
concentration of the probe was increased to 1.0 mM, the
uptakes were very significant. To our surprise, we found that
there was no further improvement for lengthening incubation
time beyond 15 minutes in either mature or immature DCs.
These results suggest that the delivery-assisted transport of
FITC into DCs was very efficient and could be achieved in a
notably short period of time.
FACS provides quantitative values, but it does not give an
overall picture of cellular distribution. In the next assay, we
examined the dynamic localization of the probe in mature
and immature DCs using confocal microscopy. Figure 2
shows that the morphology of immature and mature DCs
can be distinguished readily using the differential integration
contrast (DIC) channel. The former have a round shape
whereas the latter have a dendrite-like features on the cell
surface. A 15-minute incubation of MPA11P-FITC (0.2 mM)
resulted in remarkable fluorescent signals in both mature and
immature DCs. However, neither showed any degree of
uptake for an equivalent concentration of FITC (Figure 2A).
Furthermore, confocal microscopic data showed that the
delivery module carried the fluorescent dye across the cell
membrane and homing to the cytoplasm. We also observed
that immature DCs phagocytosed the probe slightly more
effectively than do their mature counterparts. Quantitative
Figure 1. Mature versus immature DCs on the ability to uptake the probe.
Half of the isolated DCs was incubated with FITC or the MAP11P-FITC probe
at two different concentrations and times. Cell-associated materials were
quantified by FACS analysis. The other half of the population was allowed to
mature for 2 days, followed by a similar study. a The fluorescent signals were
2- and 4-fold compared to the control for mature and immature DCs,
respectively. b The signal was 3-fold compared to the control for both mature
and immature DCs. The results shown represent the mean of two
independent experiments.
Figure 2. Comparison of the uptake of DCs at different stages of cellular development. (A) Confocal microscopy on live cells plated on the eight-well Nalge Nunc
chambers on incubation with either 0.2 M of a fluorescent dye of FITC or with probe MPA11P-FITC for 15 minutes at 37jC. The morphologies of mature and
immature cells are distinguished on the DIC channel. Images were color-coded green for FITC. Fluorescence images indicate that the delivery module shuttles the
dye inside DCs with remarkable efficiency. The signal is perinuclear and mostly cytosolic. To generate a better localization, the fluorescence image was merged
with DIC. (B) Immature DCs uptake better than mature counterparts. Bone marrow–derived DCs were isolated; on day 6, half of the cells were treated with the
probe at the indicated time and the uptake was quantified by FACS analysis. LPS was added to the rest of the cells and they were allowed to grow over a period of 2
days. The mature cells were then treated in a similar manner as described for the immature counterparts. The uptake of immature DCs was, to some extent, better
at every tested concentration. The results shown represent the mean of two independent experiments.
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FACS analysis showed that it is about 1.5- to 2-fold better
(Figure 2B).
Continuing work showed that the MPA11P-FITC probe not
only crossed inside DCs effectively, but that it was also
nontoxic. As a consequence, there were no observed ad-
verse effects on cellular functionality. Figure 3A shows that
the phenotypes of the labeled and the unlabeled control cells
appear to be similar on the upregulation of the maturation
process (CD11c), expression of the costimulatory surface
molecules (CD80 and CD86), and the cytokine receptor
(CCR7). Functional assays were carried out to analyze the
levels of the secreted IL-12 and TNF-a from activated
labeled and unlabeled DCs compared to nonactivated con-
trols. ELISA analysis of the cell supernatant revealed that
IL-12 and TNF-a were about 39- and 19-fold higher, respec-
tively, in the labeled cells compared to nonactivated cells. For
comparison, under identical conditions, secretion of IL-12
and TNF-a of unlabeled cells increased about 45- and 21-
fold, respectively, after LPS-induced activation (Figure 3B).
These data suggest that labeling DCs with the MPA11P-FITC
probe might decrease the secretion of cytokines slightly,
compared to the unlabeled cells.
Next, we investigated the ability of labeled DCs to induce
T-cell proliferation. Dendritic cells were incubated with the
probe before LPS-induced maturation or were freshly la-
beled after LPS treatment. With corresponding controls, all
DCs were irradiated to halt proliferation. Designated and
diluted DCs were then cocultured with freshly prepared
splenic CD4
+ T-cells. The ability of DCs to stimulate the
proliferation of CD4
+ T-cells was assessed by a FACS assay
based on the BrdU integrations. As shown in Figure 3C,
coculturing with DCs compared to T-cells alone stimulates
CD4
+ T-cell proliferation. LPS-stimulated DCs further en-
hanced the proliferation of cocultured T-cells in all three
tested DC populations. Both pre- and postlabeling with
the probe have minimal effect on the potential of the DCs
to stimulate CD4
+ T-cells. Altogether, these data support
the notion that labeling DCs using our MPA11P-FITC probe
does not interfere with the surface receptor expression,
the phenotype, or the functions of the DCs, nor does it af-
fect the ability to communicate with T-cells through secre-
tory cytokine.
To demonstrate the possibility that this technique can be
used for in vivo application, first, we performed imaging on
phantom tubes. Half a million DCs were incubated with either
0.2 mMMPA11P-FITC probe or an equal amount of FITC as a
control for 15 minutes; and then, the cells were transferred to
the tubes that had been precasted with 5% agarose gel.
Figure 3. Phenotypical and functional study of labeled DCs. (A) FACS profiles of surface markers expression of CD11c, CD80, CD86, and CCR7. The shaded
histogram represents the indicated specific antibody; the open histogram is the isotype control antibody. (B) Isolated bone marrow–derived DCs were divided into
three groups. The first group was treated with buffer; the second and third groups were activated with LPS, and one of them was treated with buffer as control and
the other with the MPA11P-FITC probe. Secretions of IL-12 and TNF-a were measured in the supernatants using ELISA. Results are shown as means ± SD of
triplicate values and statistical analysis was performed using Student’s t test, P < .05. (C) The abilities of the labeled and mature DCs to induce CD4
+ T-cell
proliferation were compared with the ability of the unlabeled mature DCs. In this assay, the incorporation of BrdU into the newly synthesized T-cells was stained
with specific anti –BrdU fluorescent antibodies. The degree of cell-associated BrdU was then measured by FACS analysis. Labeling DCs when they were immature
(Pre) or mature (Post) without activation by LPS did not induce T-cell proliferation; consequently, we observed the levels of T-cell counts to be as low as the control.
In contrast, activation of DCs with LPS in either mature (LPS + Post) or immature status (Pre + LPS) stimulated CD4
+ T-cell proliferation.
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Images were obtained using the IVIS optical imaging device.
The fluorescent signals of labeled cells from the phantom
tubes were remarkably strong (Figure 4), whereas the FITC-
labeled cells did not show any signal (P < .0001).
Next, we determined whether optical imaging could be
used to monitor cell migration and homing in vivo. The
labeled DCs were adaptively transferred into C57BL/6 mice
(n = 5) by s.c. injection. The LN was surgically exposed
24 hours after injection, and the fluorescent signal was de-
tected in the LN with a distinct intensity compared to the
control muscle tissue (Figure 5). Dual-channel fluorescence
microscopy of the dissected LN showed a strong signal, and
this corroborated the in vivo imaging data. Notably, the
fluorescent signal merged with CD3-specific T-cell markers,
indicating that DCs inside the LN preferentially accumulated
in the T-cell area (paracortex).
Discussion
The hypothesis that tumor antigen–bearing DCs could be
used as a vaccine to prevent tumors or to kill existing tumors
forms the underlying basis for many clinical trials designed
to test the possibility of using DCs to induce immunity against
antigens associated with many tumors including breast,
lung, prostate, and melanoma [22]. However, many issues
need to be resolved in basic research; one of the priorities is
to examine cellular functionality after the in vitro stimulation
with tumor antigens, as well as the mobility and cellular fate
after adaptive transferred of the cells in the host system.
In vivo detection of the migration of DCs would be an
important tool for further research of the role DCs play in
developing effective cancer vaccines. In this work, we
demonstrate that it is feasible to track the migration of DCs
in vivo using a whole-mouse optical imaging system. Sev-
eral experiments carried out in our laboratory indicated that
DCs cannot appreciably uptake imaging probes (data not
shown). Therefore, we propose to use a delivery-assisted
strategy to address this problem. With the assistance of
the delivery module, FITC can be shuttled inside DCs suffi-
ciently in both mature and immature cells, and in a remark-
ably short period of time (15 minutes). Other researchers
have shown that the average uptake time of materials by
Figure 4. Mature DCs were incubated with the MPA11P-FITC probe for 15
minutes and the fluorescent signal was readily detected in phantom imaging.
Figure 5. Images of a mouse injected s.c. with DCs labeled with 6 M MPA11P-FITC probe. (A) Twenty-four –hour postinjection, the digital image showed the
exposed inguinal LN as indicated by an arrowhead. (B) Intravital optical imaging of labeled DCs migration to the LN. (C) False-color merged image of the LN. (D)
The LN was dissected for ex vivo imaging compared with the muscle; an arrow indicates the muscle. (E) Color-coded image. (F) Immunohistological analysis of a
frozen section of a LN. Partial view of a LN at the follicle area: the labeled DCs (green) are associated with Rhodamine-labeled CD3 (red) indicating that the DCs
are in the T-cell area. The image was taken using a confocal microscope; original magnification, 40.
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the DCs without assisted delivery is about 18 to 24 hours
[23,24]. The MPA11P-FITC probe was internalized inside the
cytoplasm; this is similar to what we observed with other cell
types [17,25]. We did not observe any detectable signal
when DCs were incubated with equivalent concentrations
of FITC dye.
From an imaging point of view, we prefer to incubate the
molecular probes in the mature stage to avoid inference with
the process of antigen uptake. To this end, we decided to
compare the uptake rates of immature DCs compared to
their mature counterparts. Extensive FACS study showed
that the former could uptake the MPA11P-FITC probe 1.5- to
2-fold better than the latter (Figure 2). This observation may
not represent every single case because the parameters
may vary slightly between probes or depend on the original
source of DCs. However, it provides some important princi-
ples regarding the suitable time frame for labeling DCs with
minimum perturbation. We did not observe any significant
changes in the phenotype or function of the DCs after the
mature DCs were loaded with the probe by a brief incubation;
the unlabeled and labeled cells expressed similar levels of
CD11c, costimulatory molecules CD80, CD86, or CCR7
(Figure 3). The labeled cells are capable of secreting IL-12
and TNF-a after activation, although with slightly less effec-
tiveness (f 10%) compared to the unlabeled cells. Further-
more, labeling DCs with MPA11P-FITC probe can
subsequently stimulate the proliferation of CD4+ T-cells
(Figure 3C). Collectively, these results strongly suggest that
we could label mature DCs with the imaging probe with
minimum perturbation of cellular functionality.
The fluorescent signal depicted from the labeled cells
was detected in a phantom experiment (Figure 4). There was
no indication of migration to distant LNs in in vivo experi-
ments. In addition, not all injected DCs could migrate to the
target tissue; we observed labeled DCs trapped in the fat
membrane deep below the animal’s skin. Even so, a portion
of the migrating DCs in the LNs could provide a strong fluo-
rescent signal compared to peripheral tissue (Figure 5, B, C,
D, and E ). Most importantly, confocal microscopic studies
revealed that the labeled DCs can home in the T-cells area
(Figure 5F ).
Taken together, our data suggest that it is necessary to
deliver a probe inside DCs for optical imaging. With a potent
delivery module, the cells can function and migrate normally.
In our view, DCs are ideal targets for imaging because the
labeled cells are terminally differentiated when transferred to
the host system. Therefore, the imaging signal is always
strong compared to imaging cells that are continuously
differentiated. We believe this technique can be used to
deliver tumor antigens for the processing and presentation
of DCs. Finally, the delivery molecule can be modified for
MRI, particularly for functionalized super paramagnetic iron
oxide nanoparticles and the Gd-DOTA scaffold.
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